Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer

Serial biopsy is a mainstay for patients on active surveillance (AS) for prostate cancer. mpMRI targeting has become a standard. It is unclear whether targeted biopsy alone reliably identifies the dominant lesion, thereby obviating the need for systematic sampling.